Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: Psychotropic Treatment Classes and Options
In this video, Laura T. Safar, MD, gives an overview of psychotropic treatment classes, their uses in the management of neuropsychiatric disorders among patients with multiple sclerosis, and important considerations for each class. She recently gave a talk on this topic at the Consortium for Multiple Sclerosis Centers Virtual Meeting.
In this video, Laura T. Safar, MD, discusses psychotropic treatment as one of several potential tools for the management of neuropsychiatric disorders among patients with multiple sclerosis.
Anamaria Shanley, MSN, APRN-C, discusses the impact of the COVID-19 pandemic, social distancing, and the transition to telemedicine on the older adults she sees in her behavioral neurology practice in Central Florida, as well as other patient populations of concern.
Anthony L. Rostain, MD, from the Perelman School of Medicine, discusses lifespan neurodevelopmental psychiatry which is a method of working collaboratively with patients and their families over the course of their growth, through all stages of life, by creating and participating in specialized health service systems where these patients can find comfort and avoid feeling measured against their “neurotypical” counterparts.
Robert S. Laitman, MD, discusses evidence supporting the reclassification of schizophrenia as a neurological disorder, his views on how reclassification could impact prognosis and recovery, and treatment interventions he says have led to meaningful recovery in his patients with schizophrenia.
A 77-year-old man with a history of hypertension and bilateral cataracts presented for a geriatric falls assessment. A recent evaluation by his primary care provider for the onset of visual hallucinations had resulted in a diagnosis of dementia with psychosis.
Laura T. Safar, MD, from Brigham and Women's Hospital, answers our questions about the use of psychotropics in patients with multiple sclerosis. Read more about her tips for managing drug-drug interactions here.
In the final installment of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA, discusses suicidality in patients with schizophrenia compared with the general population. He also outlines steps clinicians can take to help prevent suicides in their patients.
In part 3 of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA explains the importance of treating his patients’ physical and societal health in addition to their psychiatric health.
Schizophrenia is not a death sentence, says Robert S Laitman, MD, from Bronx Westchester Medical Group and SARDAA. In part 2 of this podcast series, Dr Laitman explains how his approach to treatment has helped the majority of his patients achieve meaningful recovery.